Plain-English translation of NCT06649162 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →This study is following 10,000 people with type 2 diabetes who are starting treatment with dapagliflozin/pioglitazone, a combination of two diabetes medications. Researchers want to understand how often fatty liver disease develops in people with type 2 diabetes and to see whether this medication combination might help prevent or improve that condition.
Many people with type 2 diabetes also develop fatty liver disease, which can cause serious health problems over time. This study exists to find out how common this problem is in everyday clinical practice and whether this medication combination can help protect the liver while treating diabetes.
You likely qualify if…
You likely don't qualify if…
You would take the medication as prescribed by your doctor and return for follow-up visits so researchers can monitor how the treatment is working and check for signs of liver disease. The study will track your health outcomes over time to help answer questions about how often fatty liver disease occurs in people with type 2 diabetes and whether this medication helps.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
South Korea
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment target
~10,000 participants
Started
September 2024
Primary completion
March 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shin-young Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.